Axon Enterprise
AXON
$510.28
-5.81%
Axon Enterprise is building a public safety operating system by integrating hardware devices (TASER energy weapons, body cameras, drones) with cloud software solutions for digital evidence management. As a dominant player in law enforcement technology, it holds a near-monopoly in the conducted energy device market and is expanding rapidly into AI-driven evidence analysis and drone security. The current investor narrative centers on Axon's explosive growth in AI and drone demand, with Q1 2026 revenue surging 33.7% YoY, though the stock remains down over 50% from its 52-week high, creating a debate between strong fundamentals and market skepticism.…
AXON
Axon Enterprise
$510.28
Related headlines
Investment Opinion: Should I buy AXON Today?
Rating: Buy. Thesis: Axon's accelerating revenue growth, improving profitability, and dominant market position in law enforcement technology make it a compelling growth investment, despite its high valuation. The consensus analyst rating is Buy with an average target of $673.15, implying 24.4% upside.
Supporting Evidence: Q1 2026 revenue grew 33.7% YoY to $807.3M, accelerating from 19.0% growth in Q2 2025. Net income swung to $169.3M (21.0% net margin) from a loss a year earlier. The forward P/E of 51.2x, while high, is justified by expected EPS growth to $13.89 (analyst estimate). Free cash flow TTM is positive at $19.5M, though quarterly FCF was negative due to acquisitions. The EV/Sales multiple of 15.0x reflects a premium for its software-like margins and recurring revenue.
Risks & Conditions: The biggest risks are valuation compression if growth decelerates, negative FCF from continued acquisitions, and macro sensitivity (beta 1.378). This Buy would downgrade to Hold if revenue growth falls below 25% or if the stock approaches the analyst low target of $409.68. It would upgrade to Strong Buy if the stock pulls back to the 52-week low of $339.01 while fundamentals remain intact. Overall, AXON appears fairly valued relative to its growth trajectory, but the high trailing P/E warrants caution.
Sign up to view all
AXON 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Axon's fundamental trajectory is exceptionally strong, with revenue acceleration and a dramatic profitability turnaround. The key risk is the high valuation, but the forward P/E of 51x is reasonable for a company growing at 30%+ with expanding margins. The stock's 27.5% decline over the past year appears overdone relative to fundamentals, creating a potential buying opportunity. However, the medium confidence reflects the uncertainty around sustaining growth and the stock's high beta. An upgrade to high confidence would require sustained revenue growth above 30% and positive free cash flow. A downgrade to neutral would occur if growth decelerates below 25% or margins contract.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axon Enterprise's 12-month outlook, with a consensus price target around $673.15 and implied upside of +31.9% versus the current price.
Average Target
$673.15
0 analysts
Implied Upside
+31.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$410 - $825
Analyst target range
Axon is covered by 18 analysts, with a consensus recommendation of 'Buy' (mean 1.6 on a 1-5 scale). The average target price is $673.15, implying 24.4% upside from the current price of $541.12. The distribution leans bullish, with no sell ratings and recent reaffirmations from Piper Sandler, Needham, and JP Morgan. The target range spans from a low of $409.68 to a high of $825.00. The high target of $825 assumes continued growth acceleration from AI and drone products, potentially driving multiple expansion. The low target of $409.68 prices in margin compression or competitive losses, representing 24.3% downside. The wide spread ($409.68–$825.00) indicates high uncertainty, but the average target still suggests significant upside. Recent ratings have been stable, with no downgrades in the past three months, reinforcing positive sentiment.
Bulls vs Bears: AXON Investment Factors
Axon presents a classic high-growth vs. high-valuation debate. On the bull side, revenue acceleration to 33.7% YoY, a profitability turnaround with 21% net margin, and a consensus Buy rating with 24.4% upside provide strong fundamental support. On the bear side, the stock's 27.5% annual decline, extreme trailing P/E of 355x, and negative quarterly free cash flow highlight significant risks. The single most important tension is whether Axon can sustain its growth trajectory to justify its premium valuation. If revenue growth remains above 30% and margins continue to expand, the stock could re-rate higher. However, any deceleration or margin compression could trigger a sharp sell-off toward the analyst low target of $409.68. Currently, the bull case has stronger evidence given the accelerating growth and improving profitability, but the market's skepticism reflected in the stock's decline cannot be ignored.
Bullish
- Revenue Growth Accelerating to 33.7%: Q1 2026 revenue surged 33.7% YoY to $807.3M, up from 19.0% in Q2 2025, driven by strong AI and drone demand. This acceleration outpaces most defense tech peers and supports the premium valuation.
- Profitability Turnaround with 21% Net Margin: Net income swung to $169.3M in Q1 2026 from a loss of $2.2M in Q3 2025, achieving a 21.0% net margin. Operating margin turned positive at 3.6%, demonstrating operating leverage as revenue scales.
- Analyst Consensus Buy with 24.4% Upside: 18 analysts rate AXON a Buy (mean 1.6/5) with an average target of $673.15, implying 24.4% upside from $541.12. No sell ratings and recent reaffirmations from Piper Sandler, Needham, and JP Morgan reinforce positive sentiment.
- Dominant Market Position in Law Enforcement Tech: Axon holds a near-monopoly in conducted energy devices (TASER) and is expanding into AI-driven evidence analysis and drone security. Its integrated hardware-software ecosystem creates high switching costs for customers.
Bearish
- Stock Down 27.5% Over Past Year: AXON has declined 27.5% over the past year, dramatically underperforming the S&P 500's +20.9% gain. The stock sits at 61.1% of its 52-week range, indicating persistent selling pressure despite strong fundamentals.
- Extreme Trailing P/E of 355x: At 355x trailing earnings, AXON trades at a significant premium to the broader market and its own historical range (32x-3,550x). Any earnings miss could trigger severe multiple compression.
- Negative Free Cash Flow in Q1 2026: Free cash flow was -$54.6M in Q1 2026 due to heavy acquisition spending ($549.7M). While TTM FCF is $19.5M, the negative quarterly FCF raises concerns about cash flow sustainability.
- High Beta of 1.378 Amplifies Downside Risk: With a beta of 1.378, AXON is 38% more volatile than the market. In a broad market downturn, the stock could fall significantly more than the S&P 500, as evidenced by its 60.28% max drawdown.
AXON Technical Analysis
Axon is in a pronounced downtrend, with the stock down 27.5% over the past year, significantly underperforming the S&P 500's +20.9% gain. The current price of $541.12 sits at 61.1% of its 52-week range ($339.01–$885.92), indicating it is closer to the low end. This positioning suggests the stock may be oversold, but the persistent decline warns of potential further downside if fundamentals deteriorate. Over the past three months, Axon has rallied 37.7%, and over the past month it has surged 22.1%, dramatically outperforming the S&P 500's 0.6% and 6.3% returns over those periods. This short-term momentum sharply diverges from the 1-year downtrend, signaling a potential trend reversal or a bear market rally. The strong relative strength (1-month RS of +21.5%) suggests buying pressure is building, but the 1-year RS of -48.4% confirms the long-term weakness. The 52-week low of $339.01 provides key support, while the 52-week high of $885.92 is major resistance. A breakout above $885.92 would signal a reversal of the downtrend, while a breakdown below $339.01 could accelerate selling. With a beta of 1.378, Axon is about 38% more volatile than the market, amplifying both upside and downside moves.
Beta
1.38
1.38x market volatility
Max Drawdown
-60.3%
Largest decline past year
52-Week Range
$339-$886
Price range past year
Annual Return
-31.6%
Cumulative gain past year
| Period | AXON Return | S&P 500 |
|---|---|---|
| 1m | +20.6% | +0.3% |
| 3m | +26.7% | +4.7% |
| 6m | -19.8% | +7.5% |
| 1y | -31.6% | +18.4% |
| ytd | -9.4% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXON Fundamental Analysis
Axon's revenue trajectory is accelerating, with Q1 2026 revenue of $807.3 million growing 33.7% YoY, up from 19.0% growth in Q2 2025. The Connected Devices segment, including TASER X2 ($232.9M) and Axon Body ($108.8M), drives the majority of sales, while Software and Sensors ($354.5M) is a high-margin growth driver. This acceleration is driven by strong demand for AI and drone products, as highlighted in recent earnings calls. Profitability has improved dramatically, with Q1 2026 net income of $169.3 million (net margin 21.0%) versus a net loss of $2.2 million in Q3 2025. Gross margin remains healthy at 59.1%, though slightly down from 60.4% a year ago. Operating margin turned positive at 3.6% in Q1 2026, a significant improvement from -1.3% in Q1 2025, indicating operating leverage is kicking in. Axon's balance sheet is solid, with a current ratio of 2.53 and debt-to-equity of 0.59, indicating manageable leverage. However, free cash flow was negative -$54.6 million in Q1 2026 due to heavy investment in acquisitions ($549.7M), though trailing twelve-month FCF is $19.5 million. ROE stands at 3.9%, reflecting the company's asset-heavy model, but improving profitability should drive higher returns.
Quarterly Revenue
$807345000.0B
2026-03
Revenue YoY Growth
+33.8%
YoY Comparison
Gross Margin
59.1%
Latest Quarter
Free Cash Flow
$19507000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXON Overvalued?
Since net income is positive ($169.3M in Q1 2026), the trailing P/E ratio is the primary metric. Axon trades at a trailing P/E of 355x, which is extremely high, but the forward P/E of 51.2x implies the market expects significant earnings growth. The gap between trailing and forward P/E suggests investors are pricing in a sharp earnings acceleration, consistent with the company's raised guidance. Compared to the Aerospace & Defense industry, Axon's P/S ratio of 16.4x is a premium to the sector average (data not available), but its growth rate far exceeds typical defense contractors. The EV/Sales multiple of 15.0x also reflects a premium for its software-like margins and recurring revenue. Historically, Axon's trailing P/E has ranged from 32x to 3,550x over the past five years. The current 355x is near the high end of its historical band, indicating the market is pricing in optimistic future earnings. However, the forward P/E of 51x is more moderate and suggests that if earnings materialize, the stock could be reasonably valued.
PE
355.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 32x~170x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
236.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Axon's primary financial risk is its extreme valuation. With a trailing P/E of 355x, the stock prices in years of future growth, leaving no room for error. The negative free cash flow of -$54.6M in Q1 2026, driven by $549.7M in acquisition spending, raises concerns about cash generation despite strong revenue growth. Additionally, the debt-to-equity ratio of 0.59 is manageable but could become burdensome if growth slows. The company's reliance on continued revenue acceleration (33.7% YoY) to justify its valuation means any deceleration could lead to severe multiple compression.
Market & Competitive Risks: Axon's high beta of 1.378 makes it vulnerable to broad market downturns, as evidenced by its 60.28% max drawdown. The stock's 27.5% annual decline versus the S&P 500's 20.9% gain highlights its sensitivity to macro headwinds and sector rotation away from growth stocks. Competitive risks include potential entrants in the law enforcement tech space, though Axon's near-monopoly in TASER devices provides a moat. Regulatory risks around AI and drone usage could also impact growth, as seen in Amazon's Ring privacy controversies.
Worst-Case Scenario: In a severe downturn, Axon could see its growth decelerate due to budget constraints in law enforcement or competitive losses. If revenue growth falls below 20% and margins compress, the stock could fall to the analyst low target of $409.68, representing 24.3% downside from the current price of $541.12. In an extreme scenario, the stock could revisit its 52-week low of $339.01, implying a 37.4% loss. This worst-case would likely be triggered by a combination of macro recession, earnings misses, and analyst downgrades.
FAQ
The key risks are: 1) Valuation risk: The trailing P/E of 355x leaves no room for error; any earnings miss could trigger severe multiple compression. 2) Financial risk: Negative free cash flow of -$54.6M in Q1 2026 raises concerns about cash generation despite strong revenue growth. 3) Market risk: With a beta of 1.378, AXON is highly sensitive to market downturns, as evidenced by its 27.5% annual decline versus the S&P 500's 20.9% gain. 4) Competitive risk: While Axon has a near-monopoly in TASER devices, emerging competitors in AI and drone security could erode market share. The most severe risk is a growth deceleration that could push the stock to the analyst low target of $409.68, a 24.3% downside.
The 12-month forecast for AXON is based on three scenarios. The base case (45% probability) sees revenue growth moderating to 25-30%, with the stock trading around the analyst average target of $673.15, implying 24.4% upside. The bull case (30% probability) assumes sustained growth above 30% and margin expansion, driving the stock to the high target of $825.00 (52.5% upside). The bear case (25% probability) envisions growth deceleration below 20% and margin compression, pushing the stock to the low target of $409.68 (24.3% downside) or the 52-week low of $339.01. The most likely scenario is the base case, driven by continued strong demand for AI and drone products, but the wide range reflects high uncertainty.
AXON's valuation is a mixed picture. On a trailing basis, the P/E of 355x is extremely high, indicating the stock is overvalued relative to past earnings. However, the forward P/E of 51.2x is more moderate and suggests the market expects significant earnings growth. Compared to the Aerospace & Defense industry, AXON's P/S ratio of 16.4x is a premium, but its growth rate far exceeds typical defense contractors. Historically, the trailing P/E has ranged from 32x to 3,550x, so the current 355x is near the high end. Overall, AXON appears fairly valued if it can deliver the expected earnings growth, but it is overvalued on a trailing basis.
From a risk/reward perspective, AXON offers a compelling opportunity for growth investors. The analyst consensus is Buy with an average target of $673.15, implying 24.4% upside from the current price of $541.12. The company's revenue is accelerating at 33.7% YoY, and profitability has improved dramatically with a 21.0% net margin in Q1 2026. However, the stock carries significant risk due to its high trailing P/E of 355x and negative quarterly free cash flow. It is a good buy for investors with a long-term horizon who can tolerate volatility, but may not suit conservative investors seeking stable income or low risk.
AXON is better suited for long-term investment due to its high growth trajectory and volatility. The company's revenue is accelerating at 33.7% YoY, and it is investing heavily in AI and drone technologies that could drive growth for years. However, with a beta of 1.378 and a 60.28% max drawdown, the stock is highly volatile and can experience sharp short-term swings. Short-term traders may find opportunities in the stock's momentum (up 22.1% in the past month), but the risk of a pullback is significant. A minimum holding period of 3-5 years is recommended to allow the growth story to play out and to ride out volatility. The stock pays no dividend, so it is not suitable for income investors.